Five years after the start of the pandemic, the fight over who owns the underlying technologies that made the Covid-19 ...

The UK has become the first country in the world to authorise an updated COVID-19 booster vaccine directed at the Omicron variant, giving a green light to Moderna's mRNA-1273.214 shot.

Effectiveness of 2024-25 COVID-19 vaccination against a COVID-19–associated ED/UC visit was 33% (95% confidence interval [CI] ...

The mRNA technology behind coronavirus vaccines is now being used to create bespoke vaccines for cancer patients.

“The effectiveness of the COVID vaccines can vary depending on which variants are targeted in the vaccine, which variants are circulating, and host factors,” said Shirin A. Mazumder, MD, and ...

Moderna has reported preliminary clinical ... it is also testing another version of the mRNA-based vaccine directed more closely at Omicron that could perform even better, with clinical data ...

The current COVID-19 vaccine is 33% effective at preventing emergency department or urgent care visits among adults of all ages. It also is 45% to 46% effective at preventing hospitalizations in older ...

Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U ...

This places it alongside Moderna's and Pfizer ... revolving door of new and contagious versions of Omicron. So the availability of updated vaccines is expected to be a useful tool to stave off ...

U.S. health officials are reevaluating a $590 million contract that was awarded to Moderna for the development of its bird flu vaccine, Bloomberg News reported on Wednesday, citing sources.